Payment overview · 2025
General Payments
$950.57
39 reported records · 9 companies
Healthcare provider profile · identity verified
John Tran
Allopathic & Osteopathic Physicians|Family Medicine · SAN JOSE, CA · NPI 1316444896
Verified facts
What the public records show
CMS Open Payments records show John Tran received $950.57 in general payments during 2025 across 39 reported records.
Aimmune Therapeutics, Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Creon by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $225.79 | 23.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $205.25 | 21.6% | 9 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $156.84 | 16.5% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.78 | 13.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $116.99 | 12.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.73 | 6.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.27 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.98 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.94 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $950.57 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $225.79 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $178.84 | 8 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $156.84 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $125.78 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $116.99 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $111.88 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 220 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
96 | 33 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
87 | 37 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
220 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 603 | 233 |
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 201 |
| Losartan Potassium | Losartan Potassium | 452 | 152 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 275 | 126 |
| Gabapentin | Gabapentin | 258 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 90 |
| Jardiance | Empagliflozin | 220 | 60 |
| Metformin Hcl | Metformin Hcl | 217 | 73 |
| Omeprazole | Omeprazole | 202 | 79 |
| Alendronate Sodium | Alendronate Sodium | 160 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 157 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 60 |
| Simvastatin | Simvastatin | 155 | 46 |
| Celecoxib | Celecoxib | 152 | 45 |
| Azelastine Hcl | Azelastine Hcl | 146 | 56 |
| Restasis | Cyclosporine | 144 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 68 |
| Metformin Hcl Er | Metformin Hcl | 140 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 49 |
| Amoxicillin | Amoxicillin | 116 | 81 |
| Cyclosporine | Cyclosporine | 114 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 34 |
| Januvia | Sitagliptin Phosphate | 109 | 32 |
| Trazodone Hcl | Trazodone Hcl | 107 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 44 |
| Atenolol | Atenolol | 97 | 30 |
| Creon | Lipase/Protease/Amylase | 96 | 33 |
| Azithromycin | Azithromycin | 95 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 38 |
| Loperamide | Loperamide Hcl | 87 | 61 |
| Zenpep | Lipase/Protease/Amylase | 87 | 37 |
| Vascepa | Icosapent Ethyl | 86 | 31 |
| Baclofen | Baclofen | 84 | 32 |
| Lisinopril | Lisinopril | 83 | 30 |
| Carvedilol | Carvedilol | 81 | 37 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 80 | 47 |
| Famotidine | Famotidine | 80 | 31 |
| Meclizine Hcl | Meclizine Hcl | 74 | 40 |
| Eliquis | Apixaban | 72 | 18 |
| Allopurinol | Allopurinol | 71 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 24 |
| Donepezil Hcl | Donepezil Hcl | 67 | 29 |
| Rybelsus | Semaglutide | 67 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 22 |
| Fluocinonide | Fluocinonide | 58 | 24 |
| Ketoconazole | Ketoconazole | 55 | 19 |
| Finasteride | Finasteride | 51 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Glipizide | Glipizide | 50 | 21 |
| Ibuprofen | Ibuprofen | 50 | 26 |
| Ozempic | Semaglutide | 45 | 11 |
| Furosemide | Furosemide | 44 | 18 |
| Colchicine | Colchicine | 42 | 17 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 39 | 17 |
| Hydrocortisone | Hydrocortisone | 35 | 22 |
| Montelukast Sodium | Montelukast Sodium | 35 | 19 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 32 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 11 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 31 | 21 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Benzonatate | Benzonatate | 26 | 12 |
| Fosinopril Sodium | Fosinopril Sodium | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 15 |
| Alprazolam | Alprazolam | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 19 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Prolia | Denosumab | 17 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Nystatin | Nystatin | 14 | 11 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $950.57 · 39 records | Aimmune Therapeutics, Inc. | BEXSERO, CREON, Cologuard Collection Kit, JARDIANCE, Kerendia, LINZESS, MOUNJARO, OTEZLA, REPATHA, ZENPEP, ZEPBOUND, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error